Ipsen reacts to NICE’s Cabometyx verdict
Company disappointed by institute’s failure to recommend thyroid cancer therapy for specific patient group
Read Moreby John Pinching | Apr 5, 2023 | News | 0
Company disappointed by institute’s failure to recommend thyroid cancer therapy for specific patient group
Read Moreby John Pinching | Feb 14, 2023 | News | 0
Benefits were identified with Cabometyx in combination with nivolumab across all efficacy measures
Read Moreby Lucy Parsons | Sep 21, 2021 | News | 0
Cabometyx found to reduce the risk of disease progression or death versus placebo in this patient population
Read Moreby Lucy Parsons | Apr 1, 2021 | News | 0
Opdivo plus Cabometyx doubled progression-free survival compared to those receiving Pfizer’s Sutent in a Phase III trial
Read Moreby Selina McKee | Apr 21, 2020 | News | 0
The combination significantly increased progression free survival when used as a first-line treatment
Read Moreby Anna Smith | Feb 12, 2019 | News | 0
Gilead’s CAR-T therapy Yescarta has been rejected by the Scottish Medicines Consortium (SMC) for use on NHS Scotland, but Novartis’ Kymriah was given a green light.
Read Moreby Selina McKee | Nov 15, 2018 | News | 0
Ipsen’s Cabometyx can now be used as monotherapy to treat certain patients with liver cancer following a green light from regulators in Europe.
Read Moreby Selina McKee | Oct 9, 2018 | News | 0
The Scottish Medicines Consortium has endorsed NHS funding for four therapies, offering new treatment options for acute myeloid leukaemia, Still’s disease, adrenal insufficiency and psoriatic arthritis.
Read Moreby Selina McKee | Aug 29, 2018 | News | 0
NHS funding for Ipsen’s Cabometyx is now being recommended by the National Institute for Health and Care Excellence to treat kidney cancer.
Read Moreby Selina McKee | Jun 5, 2018 | News | 0
The National Institute for Health and Care Excellence has issued a preliminary decision rejecting first-line use of Ipsen/Exelixis’ Cabometyx in renal cancer on the NHS.
Read Moreby Selina McKee | May 17, 2018 | News | 0
The European Commission has approved Ipsen/Exelixis’ Cabometyx for the first-line treatment of adults with advanced renal cell carcinoma (RCC).
Read Moreby Selina McKee | Jan 17, 2018 | News | 0
A late-stage trial assessing Ipsen and Exelixis’ Cabometyx in advanced liver cancer has been halted early after a significant improvement in overall survival was observed.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
